# Neural Appetite Pathways and Craving Trials

> Appetite Circuits and Cravings on Semaglutide New Mexico — How semaglutide New Mexico notes connect rodent brainstem and hypothalamic appetite pathways to the 2025 human alcohol use disorder randomized trial.

**Part One · Central Nervous System & Reward**

Tracing how subcutaneous semaglutide engages hindbrain and hypothalamic nuclei in rodents, where cellular mechanisms remain preclinical, and what a 2025 randomized trial measured in 48 adults with alcohol use disorder.

## Key Neural and Craving Findings

- In mice and rats (2020), subcutaneous semaglutide directly accessed the brainstem, area postrema, hypothalamic arcuate nucleus, and parabrachial nucleus.
- Rodent weight loss was driven by reduced food intake and modulated food preference without decreasing energy expenditure.
- Cellular hypotheses such as adipose-tissue browning, mitochondrial biogenesis, and autophagy come mainly from preclinical rodent studies (2024 review).
- In a 2025 Phase 2 randomized trial of 48 adults with alcohol use disorder, low-dose semaglutide reduced laboratory alcohol self-administration (beta -0.48; 95% CI -0.85 to -0.11; P = 0.01).

## What Rodent Brain Mapping Showed About Satiety and Palatability

Subcutaneous semaglutide acts on central appetite regulation in rodents by reaching specific hindbrain and hypothalamic nuclei. In the 2020 JCI Insight paper on [rodent neural appetite pathways](https://pubmed.ncbi.nlm.nih.gov/32213703/), Gabery and colleagues demonstrated that subcutaneous dosing in mice and rats lowered body weight through distributed central nervous system pathways by directly accessing the brainstem, the area postrema, the hypothalamic arcuate nucleus, and the parabrachial nucleus.

In those rodents, weight loss occurred through reduced food intake and modulated food preference without decreasing energy expenditure.

A 2024 review examining the [mechanistic action of semaglutide](https://pubmed.ncbi.nlm.nih.gov/39728000/) summarizes its actions as a potent GLP-1 analogue and notes that much of the supporting mechanistic evidence—including adipose-tissue browning, mitochondrial biogenesis, and autophagy—is preclinical and demonstrated in rodents. Keeping that species distinction explicit prevents laboratory tissue findings from being overstated as established human physiology.

![Neurobiologist in a dark indigo coat looking through a stereo microscope on a soapstone bench](images/neurobiology-bench-microscope.webp)

*Illustrative laboratory scene; in the 2020 rodent study, subcutaneous semaglutide directly accessed the brainstem, area postrema, hypothalamic arcuate nucleus, and parabrachial nucleus.*

## The 2025 Phase 2 Trial in Adults With Alcohol Use Disorder

In 2025, Hendershot and colleagues published a Phase 2 [randomized trial in alcohol use disorder](https://pubmed.ncbi.nlm.nih.gov/39937469/) in JAMA Psychiatry. The study enrolled 48 adults with alcohol use disorder and assigned them to 9 weeks of low-dose subcutaneous semaglutide or placebo. The protocol used 0.25 mg per week for four weeks, 0.5 mg per week for four weeks, and 1.0 mg for 1 week.

In the laboratory self-administration task, low-dose semaglutide reduced alcohol self-administration measured in grams consumed compared with placebo (beta -0.48; 95% CI -0.85 to -0.11; P=0.01) and predicted greater reductions in heavy drinking over 9 weeks.

When I compare this 2025 human trial alongside the 2020 rodent neuroanatomy paper, I see how the two designs complement each other. The rodent experiments identify distributed central nervous system pathways in the brainstem, area postrema, hypothalamic arcuate nucleus, and parabrachial nucleus, while the 48-participant randomized trial tests whether low-dose subcutaneous semaglutide measurably changes laboratory alcohol self-administration and heavy drinking over 9 weeks.

- **48** — Adults with alcohol use disorder randomized in the 2025 Phase 2 trial
- **9** — Weeks of low-dose subcutaneous protocol in the JAMA Psychiatry study
- **-0.48** — Beta coefficient for laboratory alcohol grams consumed (P = 0.01)

---

On Semaglutide New Mexico, I share my own notes on published research for educational reading only, offering no medical advice, clinical care, or treatment instructions.